Market Closed -
Nasdaq
16:30:00 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
0.2211
USD
|
+2.59%
|
|
+2.84%
|
-82.59%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
64.98
|
41.13
|
19.61
|
3.203
|
6.666
|
Enterprise Value (EV)
1 |
57.74
|
27.53
|
14.99
|
-6.443
|
6.418
|
P/E ratio
|
-13.9
x
|
-3.13
x
|
-1.32
x
|
-0.21
x
|
-0.25
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-15,070,930
x
|
-2,915,095
x
|
-1,069,980
x
|
422,334
x
|
-340,269
x
|
EV / FCF
|
-21.8
x
|
-6.44
x
|
-1.93
x
|
1.12
x
|
-0.8
x
|
FCF Yield
|
-4.58%
|
-15.5%
|
-51.9%
|
89%
|
-125%
|
Price to Book
|
8.55
x
|
3.04
x
|
2.96
x
|
0.48
x
|
-1.78
x
|
Nbr of stocks (in thousands)
|
548
|
770
|
931
|
1,334
|
5,249
|
Reference price
2 |
118.5
|
53.40
|
21.07
|
2.400
|
1.270
|
Announcement Date
|
20-03-12
|
21-02-12
|
22-03-03
|
23-03-31
|
24-04-01
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-3.831
|
-9.444
|
-14.01
|
-15.26
|
-18.86
|
EBIT
1 |
-0.8818
|
-3.833
|
-9.455
|
-14.03
|
-15.27
|
-18.87
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.392
|
-3.877
|
-9.458
|
-14.04
|
-15.27
|
-18.85
|
Net income
1 |
-7.392
|
-3.877
|
-9.458
|
-14.04
|
-15.27
|
-18.85
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-21.10
|
-8.523
|
-17.07
|
-15.98
|
-11.22
|
-5.004
|
Free Cash Flow
1 |
0.1111
|
-2.646
|
-4.273
|
-7.777
|
-5.734
|
-8.003
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-03-28
|
20-03-12
|
21-02-12
|
22-03-03
|
23-03-31
|
24-04-01
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-3.813
|
-2.793
|
-2.782
|
-3.564
|
-3.419
|
-4.025
|
-4.534
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.814
|
-2.795
|
-2.784
|
-3.566
|
-3.42
|
-4.021
|
-4.523
|
Net income
1 |
-3.814
|
-2.795
|
-2.784
|
-3.566
|
-3.42
|
-4.021
|
-4.523
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-4.200
|
-3.000
|
-2.100
|
-2.700
|
-2.700
|
-1.040
|
-1.080
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-12
|
22-03-03
|
22-05-13
|
22-08-12
|
22-11-10
|
23-08-14
|
23-11-14
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.03
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
7.24
|
13.6
|
4.62
|
9.65
|
0.25
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
0.11
|
-2.65
|
-4.27
|
-7.78
|
-5.73
|
-8
|
ROE (net income / shareholders' equity)
|
2,432%
|
-110%
|
-87.8%
|
-136%
|
-214%
|
-1,019%
|
ROA (Net income/ Total Assets)
|
-130%
|
-55.7%
|
-49.7%
|
-71.2%
|
-87.5%
|
-160%
|
Assets
1 |
5.67
|
6.956
|
19.02
|
19.7
|
17.46
|
11.79
|
Book Value Per Share
2 |
-1.300
|
13.90
|
17.50
|
7.110
|
5.030
|
-0.7100
|
Cash Flow per Share
2 |
0.6700
|
13.20
|
17.70
|
5.380
|
6.220
|
0.0900
|
Capex
|
-
|
0.02
|
0.02
|
0.01
|
0
|
0
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-03-28
|
20-03-12
|
21-02-12
|
22-03-03
|
23-03-31
|
24-04-01
|
|
1st Jan change
|
Capi.
|
---|
| -82.59% | 2.35M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|